Pharmacological management of X‐linked hypophosphataemia
Authors:
Open Access
- 12 September 2018
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (6) , 1188-1198
Abstract
The most common heritable disorder of renal phosphate wasting, X‐linked hypophosphataemia (XLH), was discovered to be caused by inactivating mutations in the phosphate regulating gene with homology to endopeptidases on the X‐chromosome (PHEX) gene in 1995. Although the exact molecular mechanisms by which PHEX mutations cause disturbed phosphate handling in XLH remain unknown, focus for novel therapies has more recently been based upon the finding that the bone‐produced phosphaturic hormone fibroblast growth factor‐23 is elevated in XLH patient plasma. Previous treatment strategies for XLH were based upon phosphate repletion plus active vitamin D analogues, which are difficult to manage, fail to address the primary pathogenesis of the disease, and can have deleterious side effects. A novel therapy for XLH directly targeting fibroblast growth factor‐23 via a humanized monoclonal antibody (burosumab‐twza/CRYSVITA, henceforth referred to just as burosumab) has emerged as an effective, and recently approved, pharmacological treatment for both children and adults. This review will provide an overview of the clinical manifestations of XLH, the molecular pathophysiology, and summarize its current treatment.Keywords
This publication has 98 references indexed in Scilit:
- FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortalityJournal of Clinical Investigation, 2012
- Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy HumansThe Journal of Clinical Endocrinology & Metabolism, 2011
- Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in miceProceedings of the National Academy of Sciences, 2011
- Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivoBone, 2011
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Calcitonin Administration in X-Linked HypophosphatemiaNew England Journal of Medicine, 2011
- Selective venous catheterization for the localization of phosphaturic mesenchymal tumorsJournal of Bone and Mineral Research, 2010
- Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid StatusThe Journal of Clinical Endocrinology & Metabolism, 2010
- Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 ConcentrationsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp MiceCalcified Tissue International, 2009